May 23, 2024 [Mountain View, Calif.]\u2014Materna Medical, Inc., a leading innovator in women’s pelvic
health solutions, has announced the completion of the first close of a $20 million Series B2
financing round. The round was led by InnovaHealth Partners and other key existing investors
included Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, Golden
Seeds, Band of Angels, and Houston Angel Network.<\/p>\n\n\n\n
“Materna is a first mover, aiming to transform the standard of care in labor and delivery. Imagine a
world in which women aren\u2019t injured while delivering vaginally,” commented Tracy MacNeal, Chief
Executive Officer for Materna Medical “Our nation\u2019s maternal health crisis is a clarion call for new
obstetrical technologies, and Materna is leading the way.”<\/p>\n\n\n\n
The company has successfully reached several key milestones, including obtaining over-thecounter FDA clearance for its first commercial product, the Milli Vaginal Dilator. Additionally,
clinical data from an expanded feasibility study of Materna\u2019s second product, Materna Prep, shows
substantial promise in the potential to reduce pelvic floor injury rates for women delivering
vaginally.<\/p>\n\n\n\n
Dr. Ariella Golomb, Materna\u2019s Board Chair and Partner at InnovaHealth Partners added, “We are
pleased with the Company\u2019s progress, excited about the feasibility data and look forward to its
publication later this year. The funds from Series B2 will be used to obtain FDA marketing
authorization for Materna Prep and support the commercial launch of this transformative
technology.\u201d<\/p>\n\n\n\n